ペプチド治療薬市場規模、シェア、成長分析、タイプ別、メーカー別、合成技術別、投与経路別、用途別、地域別 - 業界予測、2024～2031年

ペプチド治療薬市場規模は2022年に406億9,000万米ドルと評価され、予測期間（2024～2031年）のCAGRは5.94%で、2023年の431億1,000万米ドルから2031年には684億米ドルに成長する見通しです。

ペプチド治療薬の需要は、慢性疾患の有病率の上昇と創薬への投資の増加によって大きく成長する見込みです。患者や医療従事者の間では、これらの治療に関連する低毒性に対する認識が高まっており、市場展望はさらに拡大するとみられます。ペプチド合成における技術革新は、様々な病状に正確に対処することで知られる標的療法の採用増加によって補完され、売上を押し上げると予想されます。がんの罹患率の増加は、腫瘍学における調査ペプチド治療薬の使用を促進し、一方でバイオ医薬品研究に対する政府の資金援助は、この分野における新たな機会を明らかにします。しかし、限られた経口バイオアベイラビリティ、高い製造コスト、生物製剤との競合といった課題は、長期的な成長の可能性を妨げる可能性があります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーター分析と影響
  • 競争企業間の敵対関係
  • 代替品の脅威
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 供給企業の交渉力

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2023年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術の進歩
• 規制情勢
• ケーススタディ
• 顧客と購買基準の分析

ペプチド治療薬市場規模：タイプ別およびCAGR（2024～2031年）

• 市場概要
• ジェネリック
• 革新的

ペプチド治療薬市場規模：メーカー別およびCAGR（2024～2031年）

• 市場概要
• 社内
• アウトソーシング

ペプチド治療薬市場規模：合成技術およびCAGR（2024～2031年）

• 市場概要
• 固相ペプチド合成（SPPS）
• 液相ペプチド合成（LPPS）
• ハイブリッドテクノロジー

ペプチド治療薬市場規模：投与経路別およびCAGR（2024～2031年）

• 市場概要
• 非経口投与
• 経口投与
• 肺
• 粘膜
• その他

ペプチド治療薬市場規模：用途別およびCAGR（2024～2031年）

• 市場概要
• がん
• 代謝障害
• 心血管疾患
• 呼吸器疾患
• 胃腸障害
• 感染症
• 痛み
• 皮膚疾患
• 神経疾患
• 腎疾患
• その他

ペプチド治療薬市場規模およびCAGR（2024～2031年）

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • スペイン
  • フランス
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2023年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2021～2023年）

主要企業プロファイル

• Eli Lilly and Company
• Amgen Inc.
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Novo Nordisk A/S
• Takeda Pharmaceutical Company Limited
• AstraZeneca PLC
• Sanofi SA
• GlaxoSmithKline PLC
• Novartis AG
• Zealand Pharma A/S
• AmbioPharm Inc.
• Bachem Holding AG
• PolyPeptide Group
• Circle Pharma, Inc.
• PeptiDream Inc.
• Apitope Technology Ltd.
• Ever Neuro Pharma GmbH
• Teva Pharmaceuticals Industries Ltd.
• Arch Biopartners Inc.

結論と推奨事項

Peptide Therapeutics Market size was valued at USD 40.69 billion in 2022 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031).

The demand for peptide therapeutics is poised for significant growth driven by the escalating prevalence of chronic diseases and increased investment in drug discovery. Awareness of the low toxicity associated with these treatments among patients and healthcare professionals is likely to further enhance market prospects. Innovations in peptide synthesis are anticipated to boost sales, complemented by the rising adoption of targeted therapies known for their precision in addressing various medical conditions. The increasing incidence of cancer will catalyze the use of peptide therapeutics in oncology, while supportive government funding for biopharmaceutical research will unveil new opportunities in the sector. However, challenges such as limited oral bioavailability, high production costs, and competition from biologics may hinder long-term growth potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Peptide Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Peptide Therapeutics Market Segmental Analysis

Peptide Therapeutics Market is segmented by Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application and region. Based on Type, the market is segmented into Generic, Innovative. Based on Type of Manufacturers, the market is segmented into In-house, Outsourced. Based on Synthesis Technology, the market is segmented into Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology. Based on Route of Administration, the market is segmented into Parenteral, Oral, Pulmonary, Mucosal, Others. Based on Application, the market is segmented into Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Pain, Dermatological Disorders, Neurological Disorders, Renal Disorders, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Peptide Therapeutics Market

The peptide therapeutics market is significantly driven by the increasing prevalence of chronic diseases, attributed to unhealthy lifestyle choices and habits that have become more common globally. As conditions such as diabetes and cancer continue to rise, there is an escalating demand for more effective and safer treatment options. Peptide therapeutics are particularly favored due to their low toxicity profiles, making them an appealing alternative for patients suffering from various chronic ailments. This growing recognition of peptide treatments as viable solutions underscores their importance in the evolving landscape of medical therapies, further propelling the market forward.

Restraints in the Peptide Therapeutics Market

The Peptide Therapeutics market faces significant restraints, particularly due to the limited oral bioavailability of peptides. When ingested orally, peptides are prone to degradation by digestive enzymes, which significantly restricts their effective administration in this manner. As a result, most peptide therapeutics are delivered through invasive methods like injections. However, many patients are reluctant to choose these invasive options, as they generally favor non-invasive treatment alternatives. This limitation on administration routes poses a challenge for the growth and acceptance of peptide therapeutics in the market, as it reduces patient adherence and overall treatment satisfaction.

Market Trends of the Peptide Therapeutics Market

The peptide therapeutics market is experiencing a significant trend towards the development of oral formulations, a sector currently underexploited compared to injectables. As consumer preference shifts towards non-invasive administration methods, companies that strategically invest in research to create orally bioavailable peptides stand poised to gain a competitive edge. The challenges of oral delivery, such as stability and absorption, are substantial, but the potential rewards are immense, including increased patient compliance and expanded market share. Investments in innovative drug delivery technologies and formulations could yield transformative products, propelling industry growth and establishing new standards in peptide therapeutics by 2025 and beyond.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies
• Customer & Buying Criteria Analysis

Global Peptide Therapeutics Market Size by Type & CAGR (2024-2031)

• Market Overview
• Generic
• Innovative

Global Peptide Therapeutics Market Size by Type of Manufacturers & CAGR (2024-2031)

• Market Overview
• In-house
• Outsourced

Global Peptide Therapeutics Market Size by Synthesis Technology & CAGR (2024-2031)

• Market Overview
• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

Global Peptide Therapeutics Market Size by Route of Administration & CAGR (2024-2031)

• Market Overview
• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others

Global Peptide Therapeutics Market Size by Application & CAGR (2024-2031)

• Market Overview
• Cancer
• Metabolic Disorders
• Cardiovascular Disorders
• Respiratory Disorders
• Gastrointestinal Disorders
• Infectious Diseases
• Pain
• Dermatological Disorders
• Neurological Disorders
• Renal Disorders
• Others

Global Peptide Therapeutics Market Size & CAGR (2024-2031)

• North America, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
  • US
  • Canada
• Europe, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zealand Pharma A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AmbioPharm Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bachem Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PolyPeptide Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Circle Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PeptiDream Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apitope Technology Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ever Neuro Pharma GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arch Biopartners Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation